According to the House Oversight and Government Reform Committee, Medicare Part D makes terrific financial sense...for pharmaceutical companies. A report from the committee shows a $3.7 billion profit in the last two years for pharmaceutical companies due to more favorable reimbursements under Part D -- not a bad return on investment for the $36 million the industry has poured into campaign coffers in that same time period, according to the Center for Responsive Politics.